Alliance Global Partners initiated coverage of Matinas BioPharma with a Buy rating and 60c price target. The company is developing MAT2203 for the treatment of Invasive Aspergillosis and other fungal infections and the firm believes that the product can pass pivotal trials, be approved by the FDA, and drive revenues and ultimately profits, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTNB:
- Matinas BioPharma’s Multi-Million Share Sale and Lock-Up Deal
- Matinas BioPharma prices 33.33M shares at 30c in registered direct offering
- Matinas BioPharma Prices $10 Million Registered Direct Offering
- Matinas BioPharma Updates Presentation for Investor Outreach
- Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
